Acute stroke therapy: Beyond IV tPA

Anthony J. Furlan, MD
Medical Director, Cerebrovascular Center, Section of Stroke and Neurocritical Care, Department of Neurology, The Cleveland Clinic Foundation

Address: Anthony J. Furlan, MD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Furlan has indicated that he has received grant or research support from the Possis corporation, serves as a consultant for the Abbott and Lilly corporations, and is on the speakers’ bureau of the Bristol-Myers Squibb corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Anthony J. Furlan, MD
Medical Director, Cerebrovascular Center, Section of Stroke and Neurocritical Care, Department of Neurology, The Cleveland Clinic Foundation

Address: Anthony J. Furlan, MD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Furlan has indicated that he has received grant or research support from the Possis corporation, serves as a consultant for the Abbott and Lilly corporations, and is on the speakers’ bureau of the Bristol-Myers Squibb corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Anthony J. Furlan, MD
Medical Director, Cerebrovascular Center, Section of Stroke and Neurocritical Care, Department of Neurology, The Cleveland Clinic Foundation

Address: Anthony J. Furlan, MD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Furlan has indicated that he has received grant or research support from the Possis corporation, serves as a consultant for the Abbott and Lilly corporations, and is on the speakers’ bureau of the Bristol-Myers Squibb corporation.

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.